Interleukin‐6 as a Key Biomarker in Facioscapulohumeral Dystrophy: Evidence From Longitudinal Analyses
These findings validate IL-6 as a biomarker of FSHD1 severity and underscore its potential as an activity and progression biomarker. The correlation between IL-6, clinical scores, and MRI-based muscle composition changes highlights its potential utility for monitoring disease evolution and evaluating therapeutic responses in FSHD1 patients.
Authors
- Emanuela Martinuzzi (ORCID: https://orcid.org/0000-0001-5832-951X)
- Jérémy Garcia
- Angela Rita Puma (ORCID: https://orcid.org/0000-0002-4218-6128)
- Nicolas Glaichenhaus (ORCID: https://orcid.org/0000-0002-8997-0470)
- Federico Torre (ORCID: https://orcid.org/0000-0002-7254-8265)
- Andra Ezaru (ORCID: https://orcid.org/0009-0000-0794-3157)
- Manuela Gambella
- Luca Jacopo Pavan (ORCID: https://orcid.org/0000-0001-9172-233X)
- Sabrina Sacconi (ORCID: https://orcid.org/0000-0002-0246-1455)
- Luisa L. Villa (ORCID: https://orcid.org/0000-0003-4074-2335)
- Jonathan Pini (ORCID: https://orcid.org/0000-0002-0882-4472)
- Michele Cavalli
- Abderhmane Slioui
- Sandra Dhifallah
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Princess Grace Hospital Centre (MC)
- Institut de Recherche sur le Cancer et le Vieillissement de Nice (FR)
- Hôpital Pasteur (FR)
- Institut de Pharmacologie Moléculaire et Cellulaire (FR)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-10-07
- DOI
- https://doi.org/10.1002/acn3.70210
- Citations
- 1
- Primary Topic
- Shoulder Injury and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.01